BR9710752A - Inbidores de metaloprotease de sulfonamida de tiol - Google Patents

Inbidores de metaloprotease de sulfonamida de tiol

Info

Publication number
BR9710752A
BR9710752A BR9710752A BR9710752A BR9710752A BR 9710752 A BR9710752 A BR 9710752A BR 9710752 A BR9710752 A BR 9710752A BR 9710752 A BR9710752 A BR 9710752A BR 9710752 A BR9710752 A BR 9710752A
Authority
BR
Brazil
Prior art keywords
metalloprotease inhibitors
sulfonamide
thiol
thiol sulfonamide
metalloprotease
Prior art date
Application number
BR9710752A
Other languages
English (en)
Inventor
Gary Decrescenzo
Zaheer S Abbas
John N Freskos
Daniel P Getman
Robert M Heintz
Brent V Mischke
Joseph J Mcdonald
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of BR9710752A publication Critical patent/BR9710752A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9710752A 1996-07-22 1997-07-22 Inbidores de metaloprotease de sulfonamida de tiol BR9710752A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2204096P 1996-07-22 1996-07-22
PCT/US1997/012873 WO1998003166A1 (en) 1996-07-22 1997-07-22 Thiol sulfonamide metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
BR9710752A true BR9710752A (pt) 1999-08-17

Family

ID=21807509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710752A BR9710752A (pt) 1996-07-22 1997-07-22 Inbidores de metaloprotease de sulfonamida de tiol

Country Status (14)

Country Link
EP (1) EP0939629A4 (pt)
JP (1) JP2000515153A (pt)
KR (1) KR20000067964A (pt)
CN (1) CN1238688A (pt)
AU (1) AU740263C (pt)
BR (1) BR9710752A (pt)
CA (1) CA2260860A1 (pt)
CZ (1) CZ16899A3 (pt)
IL (1) IL128080A0 (pt)
NO (1) NO314035B1 (pt)
NZ (1) NZ333825A (pt)
PL (1) PL331338A1 (pt)
RU (1) RU2202540C2 (pt)
WO (1) WO1998003166A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003851A3 (en) 1997-07-22 2002-10-28 Shionogi & Co Pharmaceutical composition for the treatment or prevention of glomerulopathy
EP1132379A4 (en) 1998-09-21 2005-02-16 Takeda Pharmaceutical THIOL DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
CN1224612C (zh) * 1999-01-27 2005-10-26 惠氏控股有限公司 炔基磺酰胺硫醇tace抑制剂
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
AU773273B2 (en) * 1999-02-26 2004-05-20 Bristol-Myers Squibb Company Novel sulfonamide compounds and uses thereof
WO2000063194A1 (fr) * 1999-04-19 2000-10-26 Shionogi & Co., Ltd. Derives de sulfonamide possedant des noyaux oxadiazole
AU6049800A (en) * 1999-07-16 2001-02-05 G.D. Searle & Co. Method of changing conformation of a matrix metalloproteinase
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
EP1088815A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
CN1366524A (zh) * 2000-04-07 2002-08-28 三星电子株式会社 磺胺衍生物作为基质金属蛋白酶抑制剂
WO2002003994A1 (en) * 2000-07-12 2002-01-17 G.D. Searle & Co. N sulfonyl aminoacid derivatives as inhibitors of metalloproteinase
PT1341779E (pt) 2000-12-13 2006-10-31 Wyeth Corp Sulfonamidas heterociclicas inibidoras da producao de beta-amiloide
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
WO2002100846A1 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
WO2003103660A1 (en) 2002-06-11 2003-12-18 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1449538A1 (en) 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
CN1780829B (zh) 2003-03-31 2010-12-29 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
EP1493740A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés de 5-fluoro-thiophene, leur procédé de preparation, les compositions pharmaceutiques les contenant et leur utilisation comme inhibiteurs de métalloprotéinases
US8193389B2 (en) * 2004-03-11 2012-06-05 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
WO2006046575A1 (ja) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. シンナミド化合物の非晶質体
NZ555326A (en) * 2004-12-07 2010-01-29 Toyama Chemical Co Ltd Novel anthranilic acid derivative or salt thereof
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
KR20080069221A (ko) 2005-11-24 2008-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 모르폴린 타입의 신나미드 화합물
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
PE20081791A1 (es) 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
US8084477B2 (en) 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP2149568A1 (en) * 2008-07-22 2010-02-03 Bracco Imaging S.p.A Aryl-sulphonamidic dimers as metalloproteases inhibitors
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
TW201141536A (en) * 2009-12-21 2011-12-01 Colgate Palmolive Co Oral care compositions and methods
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
JP6650942B2 (ja) 2014-12-17 2020-02-19 ピムコ ２６６４ リミテッド Ｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−フェニル−ベンゼンスルホンアミド化合物、及びｎ−（４−ヒドロキシ−４−メチル−シクロへキシル）−４−（２−ピリジル）−ベンゼンスルホンアミド化合物、ならびにこれらの治療上の使用
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids

Also Published As

Publication number Publication date
NZ333825A (en) 2000-10-27
NO314035B1 (no) 2003-01-20
KR20000067964A (ko) 2000-11-25
JP2000515153A (ja) 2000-11-14
AU740263C (en) 2002-05-16
WO1998003166A1 (en) 1998-01-29
AU3890397A (en) 1998-02-10
RU2202540C2 (ru) 2003-04-20
NO990247L (no) 1999-03-19
IL128080A0 (en) 1999-11-30
CN1238688A (zh) 1999-12-15
CZ16899A3 (cs) 1999-08-11
CA2260860A1 (en) 1998-01-29
EP0939629A4 (en) 2002-07-17
PL331338A1 (en) 1999-07-05
NO990247D0 (no) 1999-01-20
AU740263B2 (en) 2001-11-01
EP0939629A1 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
BR9710752A (pt) Inbidores de metaloprotease de sulfonamida de tiol
NO993587D0 (no) Sulfonamid-metalloprotease-inhibitorer
NO20000464D0 (no) Acykliske metalloprotease-inhibitorer
DE69827984D1 (de) Sulfonamidderivate
DK0927168T3 (da) 1,3-diheterocykliske metalloproteaseinhibitorer
ATE259352T1 (de) Cysteine protease inhibitoren
DE69718480D1 (de) Heterocyclische metalloprotease inhibitoren
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DK0923561T3 (da) Heterocykliske metalloproteaseinhibitorer
LV12150A (lv) Farneziltransferazes inhibitori
NO20004949L (no) Sulfonamidderivater
ATE239755T1 (de) Thrombin inhibitoren
DK0956294T3 (da) Thrombininhibitorer
DE69730033D1 (de) Spirocyclisch metalloprotease inhibitoren
PT1047450E (pt) Combinacoes inibidor ace - inibidor mmp
NO990896D0 (no) Bidentate metalloproteaseinhibitorer
NO20003814D0 (no) Trombininhibitorer
NO983283D0 (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
ATE282629T1 (de) Thrombininhibitoren
FI980973A (fi) Kaksoisalkaloitu rikinpoisto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1898 DE 22/05/2007.